Lilly, Japanese Firm to Swap Product Rights: Eli Lilly and Co. said it will transfer its capsule manufacturing business to Japan's Shionogi & Co. The agreement will give Shionogi ownership of Lilly's Qualicaps operations in Japan, the United States and other countries. Osaka-based Shionogi will make an undisclosed payment to Lilly and transfer to Lilly the marketing rights to the insulin medicine Humulin in Japan. "This is an excellent opportunity for Shionogi to extend its successful operation of the empty hard gelatin capsule business in Japan to the rest of the world," President Kazuo Yoshitoshi said.
From Times Staff and Wire Reports
Copyright © 2019, Los Angeles Times